Doron Therapeutics Inc.
Doron Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative biologic therapies for osteoarthritis. Their lead product, MOTYS™, is a Phase 3 ready intra-articular biologic derived from placental tissue, designed to provide anti-inflammatory, tissue-protective, and regenerative effects to treat osteoarthritis. The company's mission is to help people regain mobility and improve quality of life through advanced biotechnologies.
Industries
Nr. of Employees
small (1-50)
Products
Placental tissue-derived intra-articular biologic (Phase 3–ready)
A cell-free, terminally sterilized biologic derived from placental tissue intended for single intra-articular injection to address osteoarthritis via anti-inflammatory, anti-catabolic, and pro-anabolic mechanisms; described as having demonstrated preclinical efficacy and clinical safety/efficacy signals.
Placental tissue-derived intra-articular biologic (Phase 3–ready)
A cell-free, terminally sterilized biologic derived from placental tissue intended for single intra-articular injection to address osteoarthritis via anti-inflammatory, anti-catabolic, and pro-anabolic mechanisms; described as having demonstrated preclinical efficacy and clinical safety/efficacy signals.
Services
Design and conduct of IND Phase 1 safety studies, open-label real‑world cohorts, and randomized controlled trials to generate safety and efficacy data for intra-articular biologics.
Coordination and management of external CROs, CMOs, consultants, and advisors to run development, manufacturing, and regulatory activities under an outsourced model.
Design and conduct of IND Phase 1 safety studies, open-label real‑world cohorts, and randomized controlled trials to generate safety and efficacy data for intra-articular biologics.
Coordination and management of external CROs, CMOs, consultants, and advisors to run development, manufacturing, and regulatory activities under an outsourced model.
Expertise Areas
- Regenerative medicine biologics development
- Clinical trial design and execution (Phase 1–3, RCT, RWE)
- Preclinical efficacy testing in osteoarthritis models
- Proteomics and biofactor analysis
Key Technologies
- Placental tissue-derived biologics
- Secretome-based therapeutic processing
- Extracellular matrix–preserving processing
- Proteomic profiling